Ghaziabad, India

Praveen Khullar

This inventor holds 1 USPTO granted patent. Top assignee: Dabur Pharma Limited. Active years: 2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Praveen Khullar. Retrieved from https://idiyas.com/inventor/praveen-khullar-a5974so8

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Praveen Khullar: Innovator in Pharmaceutical Formulations

Introduction

Praveen Khullar is a notable inventor based in Ghaziabad, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of stabilized formulations for anticancer drugs. His work is essential in enhancing the efficacy and stability of critical medications.

Latest Patents

Praveen Khullar holds a patent for a stabilized pharmaceutical composition that includes an anticancer drug and a solvent such as Polyethoxylated castor oil, also known as cremophor. This formulation may also contain other suitable solubilizers for human administration, like dehydrated alcohol. The compositions he developed using purified polyethoxylated castor oil significantly enhance the stability of paclitaxel in these formulations.

Career Highlights

Praveen Khullar is currently associated with Dabur Pharma Limited, where he continues to innovate in the pharmaceutical sector. His work focuses on improving drug formulations to ensure better patient outcomes and increased drug stability.

Collaborations

Some of his notable coworkers include Anand C Burman and Rama Mukherjee, who contribute to the collaborative efforts in research and development at Dabur Pharma Limited.

Conclusion

Praveen Khullar's contributions to pharmaceutical formulations demonstrate his commitment to advancing medical science. His innovative work in stabilizing anticancer drugs is vital for improving treatment options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…